MEI Recognized by MM&M as Top 100 Medical Marketing and Communications Company

NEW YORK, June 29, 2020 /PRNewswire/ — MEI, a leading AI-driven medical communications and commercialization solutions provider, was recently recognized in the MM&M Top 100 report, which identifies the leading companies in medical marketing and communications.

The 2020 Agency 100 contains a full profile of MEI, (https://www.mmm-online.com/agency-100/agency-100-2020-mei/), which includes detailed information about revenue, staff size, and client/brand engagements.

Based in New York City, MEI combines data science, medical strategy, and creative expertise to tackle complex challenges across disease states for both US and global clients. The value of this analytics-driven approach is evidenced in the significant revenue growth MEI saw in 2019, most of which can be attributed to new business won through referrals from current clients.

“Our key differentiator is leveraging proprietary analytics in everything from patient-finding to identifying influential thought-leaders who are most able to impact clinical behavior of others in their network,” said Curtis Herrmann, EVP, Account Services. “By doing this, we’ve been able to maximize the clinical and commercial success of our clients’ brands.”

Herrmann also cited MEI’s expertise in optimizing virtual engagements as a core driver of MEI’s growth.

About MEI

MEI specializes in analytics-based marketing that sets your brand up for success prelaunch and ensures commercial impact through launch and beyond. Our unique approach applies a powerful combination of data-driven solutions, medical expertise, and strategic creativity to guide brands to their highest potential.

Visit MEI online at http://www.mei-nyc.com/

View original content:http://www.prnewswire.com/news-releases/mei-recognized-by-mmm-as-top-100-medical-marketing-and-communications-company-301085431.html

SOURCE MEI

Staff

Recent Posts

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

15 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

15 hours ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

15 hours ago